OncoImmune: Merck's Shares Acquisition Of OncoImmune
Goodwin Procter LLP advised OncoImmune on the deal. OncoImmune announced its definitive agreement pursuant to which Merck (NYSE: MRK), through a subsidiary, will acquire all outstanding [...]
Read full article »
OncoImmune is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of cancer and autoimmune diseases.
Read more